Portal de Periódicos da CAPES

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

2011; Elsevier BV; Volume: 29; Issue: 32 Linguagem: Inglês

10.1016/j.vaccine.2011.05.025

1873-2518

Dan H. Barouch, Sandra V. Kik, Gerrit Jan Weverling, Rebecca Dilan, Sharon L King, Lori F. Maxfield, Sarah Clark, David Ng’ang’a, Kara Brandariz, Peter Abbink, Faruk Sinangil, Guy de Bruyn, Glenda Gray, Surita Roux, Linda‐Gail Bekker, Athmanundh Dilraj, Hannah Kibuuka, Merlin L. Robb, Nelson L. Michael, Omu Anzala, Pauli N. Amornkul, Jill Gilmour, John Hural, Susan Buchbinder, Michael S. Seaman, Raphael Dolin, Lindsey R. Baden, Angela Carville, Keith G. Mansfield, Maria Grazia Pau, Jaap Goudsmit,

Viral Infections and Outbreaks Research

Recombinant adenovirus serotype 5 (rAd5) vaccine vectors for HIV-1 and other pathogens have been shown to be limited by high titers of Ad5 neutralizing antibodies (NAbs) in the developing world. Alternative serotype rAd vectors have therefore been constructed. Here we report Ad5, Ad26, Ad35, and Ad48 NAb titers in 4381 individuals from North America, South America, sub-Saharan Africa, and Southeast Asia. As expected, Ad5 NAb titers were both frequent and high magnitude in sub-Saharan Africa and Southeast Asia. In contrast, Ad35 NAb titers proved infrequent and low in all regions studied, and Ad48 NAbs were rare in all regions except East Africa. Ad26 NAbs were moderately common in adults in sub-Saharan Africa and Southeast Asia, but Ad26 NAb titers proved markedly lower than Ad5 NAb titers in all regions, and these relatively low Ad26 NAb titers did not detectably suppress the immunogenicity of 4 × 1010 vp of a rAd26-Gag/Pol/Env/Nef vaccine in rhesus monkeys. These data inform the clinical development of alternative serotype rAd vaccine vectors in the developing world.